For research use only. Not for use in humans.

Lirilumab (Anti-KIR)

Synonyms: IPH2102 Cat.No.A2419 Purity:99%

Lirilumab (Anti-KIR) is a fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. MW: 150 kD.

Quality Control

Batch: A241901 Purity: 99% Protein concentration: 5.665mg/ml Endotoxin Level: ＜1EU/mg

Cited in Nature Medicine for its top-tier quality
COA
SDS
Datasheet

Mechanism of Action

Description	Lirilumab (Anti-KIR) is a fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. MW: 150 kD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1000676-41-4
Molecular Weight	150 kDa
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100 mM Pro-Ac, 20mM Arg, pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.